Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × talazoparib × Endocrine × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9 Other solid neoplasm 8 Gynecologic 6 Other hematologic neoplasm 5 Thoracic 4 Genitourinary 4 Gastrointestinal 4 Tumor-Agnostic 3 Myeloid 2 Sarcoma 1 NET 1 Lymphoid 1 Head & Neck 1 Endocrine 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 13 Magnetic Resonance Spectroscopy 7 lutetium Lu 177 dotatate 6 Cisplatin 5 gallium Ga 68 dotatate 4 Specimen Handling 4 Nivolumab 4 Fluorodeoxyglucose F18 4 pasireotide 3 Positron Emission Tomography Computed Tomography 3 Etoposide 3 Carboplatin 3 (177)Lu-DOTA-EB-TATE 3 pembrolizumab 2 olaparib 2 dabrafenib 2 amino-acid, glucose, and electrolyte solution 2 Trastuzumab 2 Radiotherapy 2 Radiation 2 Photochemotherapy 2 Paclitaxel 2 Octreotide 2 Lutetium-177 2 Ipilimumab 2 Iodine-131 2 Ga(III)-DOTATOC 2 FAPI-46 2 Doxorubicin 2 Cyclophosphamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡